ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi boosts vaccines with a $685 million investment

by Rick Mullin
June 20, 2020 | APPEARED IN VOLUME 98, ISSUE 24

Sanofi plans to spend $550 million on a vaccine-manufacturing facility in Neuville-sur-Saône, France, a 5-year project ­expected to create 200 full-time jobs. Sanofi will also invest $135 million in an R&D facility in Marcy-l’Étoile. Geared toward meeting production needs in any future pandemics, the plant will feature a central unit housing several modules that can make 3–4 vaccines simultaneously. Sanofi and GlaxoSmithKline announced in April that they are collaborating on the development of an adjuvanted COVID-19 vaccine, for which the French firm will contribute an antigen based on recombinant DNA technology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment